share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/11/01 05:01

Moomoo AI 已提取核心信息

NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics has entered into a Standby Equity Purchase Agreement with YA II PN, LTD. (Yorkville) on October 31, 2024, securing access to up to $30 million in equity financing. The agreement grants the company the right to sell ordinary shares to Yorkville over a 36-month period at a 3% discount to the lowest three-day VWAP.The company will issue 224,697 ordinary shares to Yorkville as commitment shares and pay a $25,000 structuring fee. The purchase agreement includes restrictions limiting Yorkville's beneficial ownership to 4.99% of outstanding voting shares. The financing arrangement is subject to SEC registration requirements and customary closing conditions.Implementation of the agreement requires filing and SEC approval of a registration statement covering both commitment shares and future advance shares. The shares are being offered under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D, with Yorkville representing as an accredited investor purchasing for investment purposes.
NeuroSense Therapeutics 于2024年10月31日与 YA II PN, LTD. (Yorkville) 签署了一份备用股权购买协议，确保获得高达3000万美元的股权融资。该协议赋予公司在36个月内以最低三日VWAP的3%折扣向Yorkville出售普通股的权利。公司将向Yorkville发行224,697股普通股作为承诺股，并支付25000美元的结构费用。购买协议包括限制条款，限制Yorkville的有利所有权不超过4.99%的未偿还投票股。该融资安排须遵循SEC注册要求和惯例成交条件。实施该协议需要提交并获得SEC对包括承诺股和未来预付款股的注册声明的批准。这些股份在证券法第4(a)(2)节和监管D第506条下发售，Yorkville作为合格投资者，代表其购买用于投资目的。
NeuroSense Therapeutics 于2024年10月31日与 YA II PN, LTD. (Yorkville) 签署了一份备用股权购买协议，确保获得高达3000万美元的股权融资。该协议赋予公司在36个月内以最低三日VWAP的3%折扣向Yorkville出售普通股的权利。公司将向Yorkville发行224,697股普通股作为承诺股，并支付25000美元的结构费用。购买协议包括限制条款，限制Yorkville的有利所有权不超过4.99%的未偿还投票股。该融资安排须遵循SEC注册要求和惯例成交条件。实施该协议需要提交并获得SEC对包括承诺股和未来预付款股的注册声明的批准。这些股份在证券法第4(a)(2)节和监管D第506条下发售，Yorkville作为合格投资者，代表其购买用于投资目的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日